Abstract: INTRODUCTION Glioblastoma, the most common malignant brain tumor, exhibits a poor prognosis with little therapeutic progress in the last decade. Novel treatment strategies beyond the established standard of care with temozolomide-based radiotherapy are urgently needed. AREAS COV-ERED We reviewed the literature on glioblastoma with a focus on phase III trials for pharmacotherapies and/or innovative concepts until December 2015. EXPERT OPINION In the last decade, phase III trials on novel compounds largely failed to introduce efficacious pharmacotherapies beyond temozolomide in glioblastoma. So far, inhibition of angiogenesis by compounds such as bevacizumab, cediranib, enzastaurin or cilengitide as well as alternative dosing schedules of temozolomide did not prolong survival, neither at primary diagnosis nor at recurrent disease. Promising strategies of pharmacotherapy currently under evaluation represent targeting epidermal growth factor receptor (EGFR) with biomarker-stratified patient populations and immunotherapeutic concepts including checkpoint inhibition and vaccination. The clinical role of the medical device delivering 'tumor-treating fields' in newly diagnosed glioblastoma which prolonged overall survival in a phase III study has remained controversial. After failure of several phase III trials with previously promising agents, improvement of concepts and novel compounds are urgently needed to expand the still limited therapeutic options for the treatment of glioblastoma. 
Abstract

Introduction
Glioblastoma, the most common malignant brain tumor, exhibits a poor prognosis with little therapeutic progress in the last decade. Novel treatment strategies beyond the established standard of care with temozolomide-based radiotherapy are urgently needed.
Areas covered
We reviewed the literature on glioblastoma with a focus on phase III trials for pharmacotherapies and/or innovative concepts until December 2015.
Expert opinion
In the last decade, phase III trials on novel compounds largely failed to introduce efficacious pharmacotherapies beyond temozolomide in glioblastoma. So far, inhibition of angiogenesis by compounds such as bevacizumab, cediranib, enzastaurin or cilengitide as well as alternative dosing schedules of temozolomide did not prolong survival, neither at primary diagnosis nor at recurrent disease.
Promising strategies of pharmacotherapy currently under evaluation represent targeting epidermal growth factor receptor (EGFR) with biomarker-stratified patient populations and immunotherapeutic concepts including checkpoint inhibition and vaccination. The clinical role of the medical device delivering "tumor-treating fields" in newly diagnosed glioblastoma which prolonged overall survival in a phase III study has remained controversial. After failure of several phase III trials with previously promising agents, improvement of concepts and novel compounds are urgently needed to expand the still limited therapeutic options for the treatment of glioblastoma.
Article highlights
• For patients with newly diagnosed glioblastoma, the standard of care remains temozolomide-based radiochemotherapy.
• Phase III data on bevacizumab, cilengitide, and alternative dosing schedules for temozolomide did not show a survival benefit in newly diagnosed glioblastoma
• For elderly patients with a methylated MGMT promoter, temozolomide alone is probably superior to radiotherapy alone
• In recurrent disease, no widely accepted standard of care exists. Alkylating chemotherapy either as a rechallenge with temozolomide or nitrosoureas (e.g. CCNU), and bevacizumab are currently used. The combination of bevacizumab with CCNU is not superior for OS to single agent activity of CCNU.
• Phase III data emerging in the next years will define the role of novel immunotherapeutic concepts including checkpoint inhibition and vaccination
Introduction
Glioblastoma, the most common malignant primary brain tumor, has an incidence of 3.2 per 100,000 with predominance in males according to the Central Brain Tumor Registry of the United States (CBTRUS, 2008 (CBTRUS, -2012 [1] . The prognosis for patients with glioblastoma has remained poor despite multimodal therapy. Median overall survival (OS) in a populationbased study in the US after the introduction of the standard of care consisting of surgery plus During the course of the disease, despite intense initial treatment, tumor recurrence almost inevitably occurs. For recurrent disease, no widely accepted standard of care exists.
Nitrosoureas, TMZ rechallenge or bevacizumab are among the currently used medical options for the treatment of recurrent glioblastoma [5] [6] [7] .
Main challenges in developing efficacious pharmacotherapies for glioblastoma include high genetic heterogeneity within the tumor and between different patients, rapid development of drug resistance and poor distribution of most drugs within the brain [8, 9] .
In this review, we summarize the literature on glioblastoma until December 2015 focussing on phase III trials for pharmacotherapies or innovative concepts or compounds currently used in the disease. Table 1 gives an overview on the data on completed phase III trials in newly diagnosed glioblastoma since 2005.
Alkylating chemotherapy
Temozolomide and the standard of care in newly diagnosed glioblastoma
TMZ, an imidazotetrazinone prodrug, is characterized by 100% bioavailability in plasma after oral intake and proven penetration into the cerebrospinal fluid with about 20% of the area under the curve (AUC) of that reached in plasma [10] . Its active metabolite, 5-(3-methyl triazen-1-yl)imidazole-4-carboxamide, mediates the cytotoxic effect by methylation of the O 6 position of guanine with additional alkylation at the N 7 position [10, 11] .
The landmark trial in the treatment of glioblastoma represents the phase III trial of the MGMT promoter methylation [16] More recently, it was demonstrated by two randomized trials that in elderly patients, e.g. older than 60-65 years, TMZ monotherapy in patients with glioblastoma with a methylated MGMT promoter was superior to radiotherapy alone having been the standard of care in this patient population for decades [17] [18] [19] . Based on these data, current guidelines were changed towards a biomarker-driven decision-making in elderly patients with newly diagnosed glioblastoma:
For patients with glioblastomas with an unmethylated MGMT promoter or unknown methylation status, hypofractionated radiotherapy alone remains the standard of care while in patients with tumors with a methylated MGMT promoter, TMZ without or with radiotherapy should be preferred [7] . Whether combined chemoradiotherapy in the elderly patient population is superior to radiotherapy alone is currently under evaluation in a randomized phase III trial of the NCIC-CTG and EORTC (NCT00482677) [20] . Regarding the radiation schedule, a phase III trial with 98 elderly and/or frail patients with low Karnofsky performance status (50-70%) demonstrated that a one-week course with 25 Gy in five daily fractions was not inferior to standard three-week radiotherapy (total of 40 Gy) [21] . Yet, no effort of correlation with molecular markers was made in this study, and quality of life data were inconclusive.
In recurrent glioblastoma, TMZ had been already used prior to its approval in newly diagnosed disease based on the data of 2 phase II trials, one single arm study and one randomized trial showing superiority to procarbazine [22, 23] . After establishment of the standard of care with TMZ in the newly diagnosed setting, different regimens of TMZ reexposure, especially dose-intensified schedules were evaluated for recurrent disease [24] .
Most trials were small uncontrolled single-arm studies with heterogeneous patient populations with a median OS ranging between 5.1 and 11.7 months in TMZ-pretreated patients [25] [26] [27] .
The DIRECTOR trial did not find any difference in OS comparing two dose-intensified schedules in patients with recurrent glioblastoma (TMZ 80 mg/m2 for 21 days out of 28 days versus TMZ 120 mg/m 2 for 7 days out of 14 days) [28] . Yet, DIRECTOR showed that doseintensified TMZ provides relevant tumor control only in patients with tumors with MGMT promoter methylation. In the absence of convincing data, the overall clinical benefit from dose-intensified TMZ regimens compared to the standard schedule remains doubtful.
Nitrosoureas
Nitrosoureas are a group of DNA alkylating agents characterized by their high lipid solubility and thereby ability to cross the blood-brain-barrier which led to their use in brain tumors for decades. Carmustine (BCNU), nimustine (ACNU) and fotemustine are administered intravenously while lomustine (CCNU) is given orally. Toxicity, especially bone marrow suppression and hepatic toxicity, is more prominent than with TMZ.
Before the approval of TMZ in newly diagnosed glioblastoma, nitrosoureas were frequently combined with radiotherapy in the first-line setting [29] . Following the introduction of TMZ in the first-line setting, nitrosoureas have been mainly used at recurrence.
In the last decade, several randomized clinical trials in recurrent glioblastoma chose nitrosoureas, especially CCNU as active comparator for the experimental drug.
Median OS ranged between 7.1 and 9.8 months [25, [30] [31] [32] . None of the novel pharmacotherapies proved superiority to nitrosoureas so far, indirectly confirming their activity for recurrent disease. Still, relevant toxicity, especially bone marrow suppression, limits the use of nitrosureas in glioblastoma patients.
Gliadel® wafers are a specific local application mode of BCNU shown to prolong survival in recurrent malignant glioma [33] and in newly diagnosed malignant glioma [34] . No survival benefit was seen in the latter trial when the analysis was restricted to glioblastoma only.
Although approved in many countries in the world, the use of Gliadel® wafers has probably constantly declined over the last years.
Antiangiogenic therapy
Since glioblastomas are highly vascularized tumors, pharmacotherapies inhibiting angiogenesis emerged as a promising therapeutic strategy in the last decade. Main ideas of that concept included to starve the tumor by disrupting its vessels, to induce vessel "normalization" with improved delivery of chemotherapy and to fight a non-neoplastic target with limited intrinsic development of resistance.
However, all clinical trials in glioblastoma conducted so far failed to prove efficacy of antiangiogenic compounds with regard to prolonged OS.
Bevacizumab alone and combination therapy
The pharmacological compound inhibiting angiogenesis characterized best in glioblastoma and also in other tumors represents bevacizumab, a humanized monoclonal antibody against the vascular endothelial growth factor (VEGF). Data on pharmacokinetic and bioavailability of the drug especially with regard to target inhibition are limited. Serum levels as well as the half-life of the drug in tumor patients are highly variable [35] . Based on the molecular structure, no penetration across an intact blood-brain-barrier is expected. However, in glioblastoma, a disrupted blood-brain-barrier may lead to an intratumoral delivery of the drug.
In clinical trials, dosing varied between 5 and 15 mg/kg every 2 or 3 weeks with the most common dose of 10 mg/kg every 2 weeks.
Typical adverse events associated with bevacizumab include arterial hypertension, thromboembolic events, cerebral hemorrhage, impaired wound healing and intestinal perforation [36, 37] .
In newly diagnosed glioblastoma, two large phase III trials (AVAGlio, RTOG 0825)
evaluating TMZ-based radiochemotherapy with or without bevacizumab failed to prove a benefit in OS [36, 37] . In both studies, a composite primary endpoint of OS and progressionfree survival (PFS) was chosen. In contrast to OS, a prolongation of PFS was observed in both including independent imaging review). Subgroup analyses were performed in order to identify those patients likely to benefit from bevacizumab. In the RTOG 0825 trial, neither the MGMT status nor a prespecified 9-gene signature identified differences between the study groups [36] . In the biomarker population of the AVAGlio trial, IDH1 wild-type tumors were analysed for subtypes according gene expression profiles suggesting a benefit of bevacizumab in the proneural subtype in contrast to the mesenchymal or proliferative subtypes [38] . Still, this was an exploratory endpoint needing confirmation in a clinical trial with corresponding pre-specified patient stratification.
Several combination approaches have been explored in order to improve the efficacy of antiangiogenic drugs, especially of bevacizumab. In newly diagnosed glioblastoma, the Glarius trial evaluated in a multicenter phase II design the combination of bevacizumab and irinotecan against standard TMZ-based radiochemotherapy in patients with glioblastoma harboring an unmethylated MGMT promoter. PFS (5.9 versus 9.7 months) but not OS (16.6 versus 17.3 months) was significantly prolonged [39] .
In recurrent glioblastoma, bevacizumab was approved in the US and many other countries but not in the European Union based on the results of 2 phase II trials achieving radiographic response rates around 30% and PFS-6 rates of 42.6 and 29%, respectively [40, 41] . However, the effect of bevacizumab on OS remained uncertain since these trials lacked a study arm without the experimental drug. The first clinical trial in recurrent glioblastoma evaluating bevacizumab with a bevacizumab-free control arm represents the Belob trial [42] . Since this trial was conducted in the Netherlands where bevacizumab is not approved, cross-over effects were virtually absent. The trial was designed as a three-arm study comparing bevacizumab versus CCNU versus the combination of both drugs. The outcome with a median OS of 12 months of the combination arm versus 8 months of each of the monotherapy arms suggested a comparable activity of single agent bevacizumab and CCNU but importantly a benefit of the combination treatment. Based on these results, the design of the EORTC-26101 trial was adapted. The trial was initially planned as a phase II study with 4 arms randomizing for bevacizumab followed by CCNU, CCNU followed by either bevacizumab or bestinvestigator's choice or the combination of both followed by best-investigator's choice after progression on the first regimen. In the adapted design, the combination of bevacizumab and CCNU was tested in phase III randomized fashion versus CCNU as a single agent in patients with first recurrence of glioblastoma. The outcome data were presented at the 2015 Society for Neuro-Oncology (SNO) Meeting. The primary endpoint, OS, was not significantly different between CCNU monotherapy (median OS 8.6 months, n=149 patients) and the combination with bevacizumab (9.1 months, n=288 patients, hazard ratio (HR) 0.95). PFS was longer in the combination arm (4.2 months, HR 0.49) compared to CCNU alone (1.5 months). Crossover to bevacizumab in the monotherapy arm occurred in 35.5% while 19% of the patients in the combination arm continued bevacizumab after tumor progression [32] .
Subgroup analyses, especially regarding MGMT promoter methylation and gene expression profiling, will be provided with the final report of the study.
In the past, many clinical trials evaluated other drug combinations to improve the efficacy of bevacizumab as a single agent in recurrent glioblastoma. So far, both cytotoxic chemotherapy, alternative antiangiogenic agents and targeted therapy failed to show substantial effects beyond single agent activity [25] . One compound merits to be mentioned: VB-111, a nonreplicating adenovirus vector with modified murine promoter expressing a proapoptotic human Fas-chimera in order to target endothelial cells with potential antiangiogenic effects was safe in phase I/II in patients with recurrent glioblastoma [43, 44] . The initial design of the phase II trial comprised monotherapy with VB-111 (3x10 12 or 1x10 13 viral particles every 2 months) until progression followed by bevacizumab. The protocol was amended to continue VB-111 with add-on of bevacizumab upon tumor progression. Overall survival was 15
months for the group with combination therapy at progression (n=24) versus 8 months for bevacizumab alone upon progression (n=22) [45] . Based on these results, a phase III trial comparing VB-111 combined with bevacizumab vs. bevacizumab is currently conducted in patients with recurrent glioblastoma (NCT02511405).
A common clinical practice in the use of bevacizumab is to continue the drug beyond progression on the drug to avoid potential rebound effects based on little retrospective data with high probability of selection bias. The phase II CABARET trial evaluated the outcome of patients randomized to continue or stop bevacizumab upon progression on either bevacizumab alone or combined with carboplatin in patients with recurrent glioblastoma. No differences in PFS or OS were reported [46] . Cediranib, a tyrosine kinase inhibitor of VEGF receptor-1,-2,-3, PDGFR and c-kit, showed similar results regarding PFS rates in phase II as bevacizumab [47] . However, neither as a single agent nor in combination with CCNU, it was superior to CCNU monotherapy in a phase III trial in recurrent glioblastoma [31] . in this patient population was found either [52] .
Enzastaurin represents another compound potentially inhibiting angiogenic pathways in glioblastoma. It is an ATP-competitive inhibitor of protein kinase C-beta involved in downstream signaling of VEGF and other pathways. In newly diagnosed glioblastoma, a single arm study for patients without methylation of the MGMT promoter missed its primary endpoint with a PFS-6 rate of 53.6% [53] .
In recurrent glioblastoma, phase II data showed radiographic response rates of 25% but limited 6-months PFS of 7% [54] . The subsequent phase III trial for recurrent disease was stopped after poor results of an interim analysis without significant differences in PFS and OS compared with CCNU [30] .
In conclusion, after failure in phase III, there is no evidence for clinical efficacy in glioblastoma of cediranib, cilengitide or enzastaurin.
Other targeted therapies
Agents targeting pathways involved in the pathogenesis of glioblastoma, in part with promising effects in other types of cancer, have been extensively evaluated in glioblastoma. A detailed discussion of these strategies, recently provided [9] , would be beyond the scope of this review. Most concepts were not developed beyond phase II because of disappointing
results.
An inhibitor of MGMT, O 6 benzylguanine (O 6 BG), was tested in a phase III design in combination with BCNU plus radiotherapy versus BCNU plus radiotherapy alone with the hypothesis to sensitize glioma cells to alkylating chemotherapy. This trial, conducted in the pre-TMZ era, was negative both with lack of OS benefit and additional toxicity in the experimental arm [55] . with high-grade glioma [57] .
Epidermal growth factor receptor (EGFR) plays a major role in the pathogenesis of glioblastoma and has been tried as a target for therapeutic purposes for years despite several negative trials, including tyrosine kinase inhibitors such as erlotinib or gefitinib [58, 59] or monoclonal antibodies such as nimotuzumab [60] . However, these trials were not conducted in biomarker-selected populations overexpressing the target. Recently, in a phase II trial in recurrent glioblastoma evaluating the ErbB family blocker afatinib, a small efficacy signal in EGFRvIII-positive tumors versus -negative tumors was seen (median PFS 3.4 versus 1.0 months) [61] . Currently tested in phase IIb/III is ABT-414, an antibody-drug conjugate targeting EGFR in its active conformation. The toxicity profile of the drug as assessed in phase I trial includes ocular adverse events such as corneal deposits and keratitis. In this trial, 5 of 18 patients in the cohort combined with TMZ and 2 of 28 patients in the monotherapy cohort had objective response. Importantly, all patients with documented radiographic response had EGFR amplification [62] . Therefore, in the subsequent clinical trials, only patients with amplified EGFR were included. In patients with newly diagnosed glioblastoma, the currently recruiting phase IIb/III trial evaluates the combination of ABT-414 with standard radiochemotherapy compared to the standard of care alone (NCT02573324). In recurrent gliobastoma, patients are randomized to ABT-414 alone or combined with TMZ and to CCNU or TMZ (NCT02343406, EORTC 1410).
Immunotherapeutic concepts
Currently the most promising field in oncology in general as well in glioblastoma represents immunotherapy including vaccination approaches and inhibition of immunosuppressive molecules [63] .
Vaccination approaches aim at mounting a tumor-specific immune response, e.g. via peptides derived from tumor-specific antigens or cell-based approaches. The most popular and best characterized peptide-based approach represents the vaccination against the variant III of EGFR (EGFRvIII) which is present in about 25% of glioblastomas but absent in normal tissue. Rindopepimut is a vaccine comprising of an EGFRvIII-derived peptide conjugated to keyhole limpet hemocyanin (KLH) serving as a carrier and is administered intradermally with granulocyte macrophage colony-stimulating factor (GM-CSF) as adjuvant. A phase II trial in patients with newly diagnosed glioblastoma (ACT III), initially planned in a randomized but open-label fashion, evaluating the addition of Rindopepimut to standard radiochemotherapy versus radiochemotherapy alone, was changed to a one-arm design due to high drop-out rates in the control arm. Gross total resection, minimal residual disease ≤1 cm 2 and absence of tumor progression after completion of radiation therapy were required for study participation. The safety profile was favorable except for local skin reactions at the injection site. PFS at 5.5 months after study entry, the primary endpoint of the trial, was 66%.
Median overall survival of 21.8 months from study entry was encouraging, although the highly selected patient population has to be taken into account. Importantly, anti-EGFRvIII antibody titers were increased at least 4-fold in 85% of the patients and EGFRvIII was eliminated in 4/6 (67%) tumor samples at recurrence after vaccination [64] . These data confirm results from 2 smaller phase II trials assessing rindopepimut in patients with newly diagnosed glioblastoma [65, 66] . Although the vaccination is thought to work best when used early in the disease with minimal residual tumor, rindopepimut has also been evaluated in recurrent glioblastoma. The Re-ACT trial randomized patients to bevacizumab plus control vaccine versus bevacizumab combined with rindopepimut. Patients in the rindopepimut arm had higher overall response rates (30% vs. 18%), PFS-6 (28% vs. 16%) and prolonged median OS (11.3 vs. 9.3 months, HR=0.57).
Potent anti-EGFRvIII immune titer generation was associated with prolonged OS [68] , which might also simply reflect immunological fitness as a prognostic factor.
Another promising neoantigen suitable for peptide-based vaccination represents mutated IDH1 (IDHR132H), a mutation occurring early in tumorigenesis and virtually absent in normal tissue. Preclinical models support this concept [69] . The currently recruiting phase I trial NOA-16 evaluates safety and immune response to the IDH1 peptide vaccine in patients with IDH1-mutated WHO grade III and IV gliomas (NCT02454634).
Another approach to induce anti-tumor immunity which will be assessed in a phase III trial is the compound ICT-107, a vaccine of patient-derived dendritic cells incubated with peptides derived from 6 tumor-associated antigens (melanoma-associated antigen 1 (MAGE-1), human epidermal growth factor receptor 2 (HER2), absent in melanoma 2 (AIM-2), tyrosinaserelated protein-2 (TRP-2), glycoprotein100 (gp100), and interleukin-13 receptor subunit alpha-2 (IL-13Rα2). Phase I data showed good tolerability, immune responses were demonstrated in one third of the patients [70] . The subsequent phase II trial randomized ICT-107 in a 2:1 manner in addition to standard radiochemotherapy in patients with newly diagnosed glioblastoma. This study showed a significantly improved PFS in the experimental arm [71] . In the subgroup of HLA-A2-positive patients immunologic response was associated with a median OS of 23.1 months for responders and 13.7 for non-responders [72] . Based on these encouraging results, a multi-center randomized, double-blind phase III trial in HLA-A2-positive patients with newly diagnosed glioblastoma has been initiated (NCT02546102).
Another vaccine based on dendritic cells, DCVax®, is currently evaluated in a phase III trial (NCT00045968). The therapeutic priniciple, injecting patient-derived dendritic cells pulsed with autologous tumor lysate was safe in a phase I trial [73] .
Beyond this trial, the OS rate at 6 months was 70% for patients receiving nivolumab alone.
Monotherapy of nivolumab was well tolerated while the combination with ipilimumab was discontinued at phase I because of limiting toxicity including colitis, cholecystitis, diabetic ketoacidosis, and confusion [75] . Nivolumab will also be tested in patients with newly diagnosed glioblastoma. A phase III trial for patients with glioblastoma and unmethylated MGMT promoter will compare standard TMZ-based radiochemotherapy with radiotherapy and nivolumab (Checkmate 498, NCT02617589). A companion trial for patients with MGMT promoter-methylated glioblastoma is planned. Similar compounds are under development, e.g. pembrolizumab (NCT02337491) or MEDI4736 (NCT02336165) currently evaluated in phase II.
Gene therapy
Virus-delivered gene therapies may in part mediate their effects via immunological mechanisms, too. A phase III trial evaluated a locally applied adenovirus-mediated gene therapy with a prodrug converting enzyme (herpes-simplex-virus thymidine kinase; sitimagene ceradenovec) followed by intravenous ganciclovir in patients with newly diagnosed resectable glioblastoma in addition to standard radiochemotherapy compared to the standard of care alone. The co-primary endpoint of the trial, median time to death or reintervention, was prolonged in the experimental group (308 days) relative to the control group (268 days), in contrast to OS which was not different in both arms [76] .
Tumor treating fields
Beyond pharmacotherapy, a novel modality of anti-tumor therapy was tested in glioblastoma:
tumor-treating fields (TTFields/NovoTTF) represents a portable device to be carried by the maintenance TMZ [77] . Accrual was stopped early for success after a pre-specified interim analysis on 315 patients. The design did not include blinding or placebo-control of the device and excluded patients with poor outcome since randomization became effective only after completion of radiotherapy and required demonstration of stable disease at that timepoint.
A randomized phase III trial in recurrent glioblastoma had previously evaluated TTFields (>20h/day) versus best physician's choice of chemotherapy. OS and PFS were not significantly different [78] . There were no major limitations regarding toxicity in both trials except for mild to moderate skin reactions. The FDA has approved the device both for newly diagnosed and recurrent glioblastoma. Since patient acceptance of this treatment is limited at present, the future place of TTFields in the treatment of glioblastoma remains to be defined.
Conclusion
In the last ten years, despite several phase III trials with previously promising compounds and concepts, little progress has been made in the treatment of patients with glioblastoma. So far, no concept added to standard TMZ-based radiochemotherapy resulted in an additional benefit, except for the prolongation of OS in one trial by the application of TTFields. Alkylating chemotherapy with TMZ using the standard schedule remains the standard of care in newly diagnosed glioblastoma. Yet, clinical trials in the subgroup of elderly patients changed the previous standard of care, that is, radiotherapy alone: in case of a methylated MGMT promoter, TMZ with or without radiotherapy is probably superior to radiotherapy alone.
Phase III trials with antiangiogenic agents, such as bevacizumab, cilengitide, cediranib or enzastaurin were negative despite promising data in phase II studies. derived from randomized phase III trials will be available in the next 1-2 years.
Expert opinion
Improvement of the still poor prognosis of patients with glioblastoma remains a major challenge. Disease heterogeneity and rapid development of resistance limit the activity of pharmacological treatment. Despite advances in the understanding of the biology of the tumor, strategies in targeting key pathogenic mechanisms such as angiogenesis failed to prolong OS. Repeatedly, agents with promising data in phase II trials failed to confirm efficacy in randomized phase III trials. Table 2 In conclusion, advances in the biological understanding of the tumor are urgently needed to be translated into clinically active compounds to improve the still limited therapeutic options in glioblastoma. • ICT-107 (dendritic cell-based vaccine): phase III (NCT02546102)
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• DCVax (Autologous dendritic cells pulsed with tumor lysate antigen): phase III (NCT00045968)
• IDH-1 peptide vaccine in patients with IDH-1 mutated tumors (Phase I, NCT02454634, ongoing)
Alkylating chemotherapy
• No pharmacotherapy so far showed superiority to either TMZ in newly diagnosed glioblastoma or nitrosoureas in recurrent disease
Biomarker-driven decision making
• MGMT promotor methylation predictive for benefit from TMZ and used for decision making in elderly patients
Targeting amplified EGFR
• Phase IIb/III trial on ABT-414 in newly diagnosed glioblastoma (NCT02573324): recruiting 
